Anisomycin (Synonyms: Flagecidin, NSC 76712, Wuningmeisu C) |
| Catalog No.GC11559 |
Anisomycin, un antibiótico aislado de Streptomyces griseus, también es un activador de JNK.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 22862-76-6
Sample solution is provided at 25 µL, 10mM.
Anisomycin, un antibiótico aislado de Streptomyces griseus, también es un activador de JNK. La anisomicina inhibe la síntesis de proteínas principalmente al bloquear la actividad de la peptidil transferasa de la subunidad ribosomal en 80S. Además, la anisomicina induce apoptosis en varios tipos celulares a través de la activación de las vías P38, JNK y ERK1/2, lo que la convierte en un fármaco quimioterapéutico prometedor para el cáncer[1-4].
La anisomicina (10-100nM; 24h) reduce la viabilidad celular de manera dependiente de la concentración en células de melanoma B16[5]. La anisomicina (1-80 ng/ml; 24h) puede activar la vía de señalización P53/P21/P27 para reducir la expresión de ICBP90, inhibir la expresión de P-CDK2 para bloquear las células en las fases S y G2/M, y, finalmente, inhibir la proliferación de las células T Jurkat[6]. La anisomicina (31.8 μM) inhibe la proliferación, migración y angiogénesis de las CTEOs al alterar la expresión del ARN antisentido NCBP2-AS2[7].
La anisomicina (5 mg/kg; i.p; 3 semanas) interfiere eficazmente en la angiogénesis del cáncer de mama al afectar la formación de la red capilar, inhibir la migración, proliferación y supervivencia celular en modelos de cáncer de mama basados en células MD-MBA-231[8]. La anisomicina (2-200 μg/kg; i.p; 30 días) aumenta los niveles de la proteína utrofina en el diafragma del ratón mdx[9].
References：
[1]. Grollman AP. Inhibitors of protein biosynthesis. II. Mode of action of anisomycin. J Biol Chem. 1967 Jul 10;242(13):3226-33. PMID: 6027796.
[2]. Hall SS, Loebenberg D, et,al. Structure-activity relationships of synthetic antibiotic analogues of anisomycin. J Med Chem. 1983 Apr;26(4):469-75. doi: 10.1021/jm00358a003. PMID: 6834379.
[3]. Schmeits PC, Katika MR, et,al. DON shares a similar mode of action as the ribotoxic stress inducer anisomycin while TBTO shares ER stress patterns with the ER stress inducer thapsigargin based on comparative gene expression profiling in Jurkat T cells. Toxicol Lett. 2014 Jan 30;224(3):395-406. doi: 10.1016/j.toxlet.2013.11.005. Epub 2013 Nov 15. PMID: 24247028.
[4]. Slipicevic A, Øy GF, et,al. Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis. Cancer Biol Ther. 2013 Feb;14(2):146-54. doi: 10.4161/cbt.22953. Epub 2012 Nov 28. PMID: 23192275; PMCID: PMC3571996.
[5]. Ushijima H, Monzaki R, et,al. Suppressive Effects of Anisomycin on the Proliferation of B16 Mouse Melanoma Cells In Vitro. Anticancer Res. 2021 Dec;41(12):6113-6121. doi: 10.21873/anticanres.15431. PMID: 34848466.
[6]. Yu C, Xing F, et,al. Anisomycin suppresses Jurkat T cell growth by the cell cycle-regulating proteins. Pharmacol Rep. 2013;65(2):435-44. doi: 10.1016/s1734-1140(13)71019-3. PMID: 23744428.
[7]. Ling L, Wen Y, et,al. Anisomycin inhibits the activity of human ovarian cancer stem cells via regulating antisense RNA NCBP2-AS2/MEK/ERK/STAT3 signaling. J Gene Med. 2024 Jan;26(1):e3571. doi: 10.1002/jgm.3571. Epub 2023 Jul 22. PMID: 37483091.
[8]. Yang W, Zhou C, et,al. Anisomycin inhibits angiogenesis, growth, and survival of triple-negative breast cancer through mitochondrial dysfunction, AMPK activation, and mTOR inhibition. Can J Physiol Pharmacol. 2022 Jul 1;100(7):612-620. doi: 10.1139/cjpp-2021-0577. Epub 2022 Jul 19. PMID: 35852219.
[9]. Hadwen J, Farooq F, et,al. Anisomycin Activates Utrophin Upregulation Through a p38 Signaling Pathway. Clin Transl Sci. 2018 Sep;11(5):506-512. doi: 10.1111/cts.12562. Epub 2018 Jun 7. PMID: 29877606; PMCID: PMC6132359.
| Experimentos celulares [1]: | |
Líneas celulares | Células B16 |
Método de preparación | Las células fueron sembradas en una microplaca de 96 pozos (6×10³ células/pozo). Después de 24 h, el medio fue cambiado por un medio fresco que contenía diferentes concentraciones de anisomicina, seguido de una incubación adicional durante 24 h. |
Condiciones de reacción | 0-100nM; 24h |
Áreas de aplicación | Una concentración de anisomicina superior a 10 nM provocó una disminución en la viabilidad celular de manera dependiente de la concentración. |
| Experimentos con animales [2]: | |
Modelos animales | Ratones SCID de seis semanas de edad (modelo de cáncer de mama con células MD-MBA-231) |
Método de preparación | Los tratamientos se iniciaron una semana después de la inoculación del tumor. Se administró anisomicina a 5 mg/kg o 100 µL de PBS vía inyección intraperitoneal. |
Forma de dosificación | 5 mg/kg; i.p; 3 semanas |
Áreas de aplicación | La anisomicina suprime significativamente el crecimiento del tumor MD-MBA-231 in vivo. |
Referencias: [1]. Ushijima H, Monzaki R,et,al. Suppressive Effects of Anisomycin on the Proliferation of B16 Mouse Melanoma Cells In Vitro. Anticancer Res. 2021 Dec;41(12):6113-6121. doi: 10.21873/anticanres.15431. PMID: 34848466. [2]. Yang W, Zhou C, et,al. Anisomycin inhibits angiogenesis, growth, and survival of triple-negative breast cancer through mitochondrial dysfunction, AMPK activation, and mTOR inhibition. Can J Physiol Pharmacol. 2022 Jul 1;100(7):612-620. doi: 10.1139/cjpp-2021-0577. Epub 2022 Jul 19. PMID: 35852219. | |
| Cas No. | 22862-76-6 | SDF | |
| Sinónimos | Flagecidin, NSC 76712, Wuningmeisu C | ||
| Chemical Name | (2R,3S,4S)-4-hydroxy-2-(4-methoxybenzyl)pyrrolidin-3-yl acetate | ||
| Canonical SMILES | O[C@@H]1[C@H]([C@@H](CC(C=C2)=CC=C2OC)NC1)OC(C)=O | ||
| Formula | C14H19NO4 | M.Wt | 265.31 |
| Solubility | ≥ 26.5mg/mL in DMSO | Storage | Store at -20°C,protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.7692 mL | 18.8459 mL | 37.6918 mL |
| 5 mM | 0.7538 mL | 3.7692 mL | 7.5384 mL |
| 10 mM | 0.3769 mL | 1.8846 mL | 3.7692 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
-
Related Biological Data
TIL-35 promoted microglial M2 polarization via suppressing JNK signaling. (A)Western blot was performed to determine protein levels of JNK and p-JNK.
HAPI cells were pre-treated with anisomycin (0.1μM; JNK signaling activator; Glpbio, Montclair, CA, USA).
Arch Biochem Biophys (2020): 108330. PMID: 32156533 IF: 4.01 -
Related Biological Data
TAK1 knockdown improves cell viability and alleviates the inflammation of H/R‑induced Caco‑2 cells. (B) Expression levels of TNF‑α, IL‑6 and IL‑1β in the five groups were determined using reverse transcription‑quan‑titative PCR.
Anisomycin, a type of JNK agonist, was purchased from GlpBio Technology and diluted to 4µM.
Exp Ther Med 23.2 (2022): 1-9. PMID: 35069839 IF: 2.443 -
Related Biological Data
Butorphanol decreases LPS‑induced apoptosis via p38/JNK/ATF2/p53 signaling. (A) Anisomycin increased the number of apoptotic cells.
Cells were pretreated with butorphanol (1, 2 and 4µM; GlpBio Technology) and/or anisomycin (1µM; GlpBio Technology Inc.).
Exp Ther Med 23.3 (2022): 1-9. PMID: 35222706 IF: 2.443 -
Related Biological Data
Knockdown of ANKRD49 downregulates MMP-2/MMP-9 expression of H1703 cells. (G, H) The levels of JNK, p-JNK, p38, p-p38, MMP-2 and MMP-9 in ANKRD49-sh H1703 cells treated with SP600125, SB203580, Anisomycin or DMSO were measured by Western blot. β-Tubulin served as an internal control. Data are expressed as means±standard deviation.
Anisomycin (20µM) (GlpBio, USA), an activator of JNK and p38 MAPK was used to pretreat ANKRD49-sh H1703 cells for 1h.
bioRxiv (2023): 2023-03. PMID: 37964204
Average Rating: 5 (Based on Reviews and 36 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *